Moreover, its prediction accuracy increased to 0.80 if we focused on 20 EGFR and KRAS wild-type patients with NSCLC, whereas there is no currently effective predictive marker of drug response for these patients. Here, KRAS is linked to non-small cell lung carcinoma.